axe

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer

ASCO Oral Presentation Reports Significantly More Patients Treatedwith Taxotere(R)-Based Chemotherapy Regimen Survived at Least ThreeYears CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Taxotere(R)(docetaxel) Injection Concentrate-based chemotherapy (Taxotere plusprednisone) maintained long-term efficacy as a treatment foradvanced (metastatic) hormone-resistant prostate cancer patients,...

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy

VIENNA, Austria, May 23, 2007-The chemotherapy drugdocetaxel currently offers the best treatment forandrogen-independent prostate cancer. That is the result of a nowpublished clinical trial that compared the efficacy of the two mostwidely used chemotherapy drugs. When using docetaxel, the risk ofdisease progression was cut by more than 50% than when using thenext-best chemotherapy drug.<...

Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...

Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium

STRASBOURG, France and VANCOUVER, April 26, 2007/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , a globalspecialty pharmaceutical and medical device company, announced thatthe two-year data from its European pivotal trial examining theVascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)")will be presented today at a scientific forum in Europe. Thetwo-year study examine...

ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)

Results Indicate Bioequivalent Pharmacokinetics With Reduced Riskof Hypersensitivity Reactions With ANX-514 SAN DIEGO, April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,today announced positive results from...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood VesselDensity and Serum PSA Levels in Prostate Tumors - LOS ANGELES and TUSTIN, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hepatitis Cvirus (HCV) infection, today announced that p...